RF&L Wealth Management’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$2.12M Sell
8,110
-360
-4% -$92.3K 1.43% 19
2026
Q2
$2.13M Sell
8,470
-250
-3% -$53.8K 1.44% 19
2026
Q1
$1.9M Sell
8,720
-8,286
-49% -$1.84M 1.42% 19
2025
Q4
$3.89M Sell
17,006
-144
-0.8% -$32.8K 2.18% 18
2025
Q3
$3.97M Sell
17,150
-410
-2% -$83.5K 2.33% 17
2025
Q2
$3.26M Sell
17,560
-170
-1% -$31.6K 2.1% 18
2025
Q1
$3.71M Sell
17,730
-200
-1% -$38.9K 2.66% 16
2024
Q4
$3.19M Sell
17,930
-250
-1% -$46K 2.25% 16
2024
Q3
$3.59M Sell
18,180
-250
-1% -$46.7K 2.54% 16
2024
Q2
$3.16M Hold
18,430
– – 2.41% 17
2024
Q1
$3.36M Sell
18,430
-500
-3% -$86.2K 2.58% 15
2023
Q4
$2.93M Sell
18,930
-95
-0.5% -$13.8K 2.44% 14
2023
Q3
$2.84M Hold
19,025
– – 2.63% 14
2023
Q2
$2.56M Sell
19,025
-300
-2% -$44K 2.34% 14
2023
Q1
$3.08M Sell
19,325
-455
-2% -$69.6K 2.99% 11
2022
Q4
$3.2M Buy
+19,780
New +$3.03M 3.29% 10

Other funds holding ABBV

RF&L Wealth Management's ABBV Position: Q3 2026 in Review

RF&L Wealth Management reduced its AbbVie (ABBV) stake by 4.3% in Q3 2026, selling an estimated $92.3K and leaving 8,110 shares worth $2.12M. The position accounts for 1.43% of the portfolio, ranked #19.

RF&L Wealth Management first reported a position in ABBV in Q4 2022 and has held it in 16 quarters since. The position peaked at $3.97M in Q3 2025. 1,321 funds tracked by Wall St. Rank hold ABBV as of Q3 2026.

  • RF&L Wealth Management held 8,110 shares of AbbVie worth $2.12M as of Q3 2026.
  • RF&L Wealth Management sold 360 AbbVie shares in Q3 2026, an estimated $92.3K.
  • AbbVie made up 1.43% of RF&L Wealth Management's portfolio in Q3 2026, its #19 holding.
  • RF&L Wealth Management first reported a position in AbbVie in Q4 2022 and has held it in 16 quarters since.
  • RF&L Wealth Management's AbbVie position peaked at $3.97M in Q3 2025.
  • 1,321 funds tracked by Wall St. Rank held AbbVie as of Q3 2026.

Based on RF&L Wealth Management's 13F filing for Q3 2026, filed 20 Oct 2026.